Evidence map›Paper›PMID 38828429›Full record

ArticleNature catalysis2024

Epistasis arises from shifting the rate-limiting step during enzyme evolution of a β-lactamase.

Christopher Fröhlich, H Adrian Bunzel, Karol Buda, Adrian J Mulholland, Marc W van der Kamp, Pål J Johnsen, Hanna-Kirsti S Leiros, Nobuhiko Tokuriki

Abstract read
In one paragraph

Article in Nature catalysis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Directed evolution of a beta-lactamase samples a wide variety of conformational states.Protein science : a publication of the Protein Society · 2025
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Christopher Fröhlich *Department of Pharmacy, UiT The Arctic University of Norway, Tromsø, Norway.ORCID 0000-0003-2682-2267
H Adrian Bunzel *Department of Biosystem Science and Engineering, ETH Zurich, Basel, Switzerland.ORCID 0000-0001-6427-368X
Karol BudaMichael Smith Laboratories, University of British Columbia, Vancouver, British Columbia Canada.ORCID 0000-0001-9312-0498
Adrian J MulhollandCentre for Computational Chemistry, School of Chemistry, University of Bristol, Bristol, UK.ORCID 0000-0003-1015-4567
Marc W van der KampCentre for Computational Chemistry, School of Chemistry, University of Bristol, Bristol, UK.ORCID 0000-0002-8060-3359
Pål J JohnsenDepartment of Pharmacy, UiT The Arctic University of Norway, Tromsø, Norway.
Hanna-Kirsti S LeirosDepartment of Chemistry, UiT The Arctic University of Norway, Tromsø, Norway.
Nobuhiko TokurikiMichael Smith Laboratories, University of British Columbia, Vancouver, British Columbia Canada.ORCID 0000-0002-8235-1829

Funding

Biotechnology and Biological Sciences Research Council BB/R016445/1
6 · The paper itself

Abstract

Epistasis, the non-additive effect of mutations, can provide combinatorial improvements to enzyme activity that substantially exceed the gains from individual mutations. Yet the molecular mechanisms of epistasis remain elusive, undermining our ability to predict pathogen evolution and engineer biocatalysts. Here we reveal how directed evolution of a β-lactamase yielded highly epistatic activity enhancements. Evolution selected four mutations that increase antibiotic resistance 40-fold, despite their marginal individual effects (≤2-fold). Synergistic improvements coincided with the introduction of super-stochiometric burst kinetics, indicating that epistasis is rooted in the enzyme's conformational dynamics. Our analysis reveals that epistasis stemmed from distinct effects of each mutation on the catalytic cycle. The initial mutation increased protein flexibility and accelerated substrate binding, which is rate-limiting in the wild-type enzyme. Subsequent mutations predominantly boosted the chemical steps by fine-tuning substrate interactions. Our work identifies an overlooked cause for epistasis: changing the rate-limiting step can result in substantial synergy that boosts enzyme activity.

Indexed as

BiocatalysisEnzyme mechanismsHydrolasesMolecular evolution

Identifiers

PMID38828429
PMCPMC11136654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.